UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Emma Walmsley
|
|||
|
b)
|
Position/status
|
Chief
Executive Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
The vesting of Ordinary Shares awarded in 2020 under the Company's
2017 Performance Share Plan and subject to an additional vesting
period of two years from the normal vesting date
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
11,642.706
|
||||
|
|
|||||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2025-05-06
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Emma Walmsley
|
|||
|
b)
|
Position/status
|
Chief
Executive Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2020 under the Company's 2017 Performance
Share Plan and subject to an additional vesting period of two years
from the normal vesting date
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4896
.
|
5,473.000
|
||||
|
|
|||||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2025-05-06
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
08, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|